FISCHER CHEMIC LTD.

Fischer Medical Ventures Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26. The report details the company's corporate identity, business activities, operational footprint, and employee statistics. Fischer Medical Ventures operates in the manufacturing and trading of medical devices and software, contributing 100% to its turnover. The company serves both national and international markets across 9 states and 7 countries, primarily through a B2B model targeting diagnostic centers, hospitals, and healthcare institutions. The BRSR filing also includes data on employee demographics, with a total of 19 permanent employees as of FY26, and notes the absence of assurance providers for the report.

Fischer Medical Ventures Limited has published its 33rd Annual Report for the financial year 2025-2026. The report details the company's 'Next Phase of Innovation-Led Growth,' highlighting achievements such as crossing ₹100 crore in consolidated revenue and gaining trust from radiologists for its MRI platforms. The company, headquartered in Vizag, operates in magnetic resonance imaging (MRI), computed tomography (CT), digital radiography, AI-powered preventive healthcare, advanced wound care, and digital health technologies. The report is available on their website and outlines strategic initiatives for scaling their imaging portfolio, accelerating technology pipelines, expanding market reach, and strengthening manufacturing capabilities. Forward-looking statements are included with a disclaimer regarding inherent risks and uncertainties.

Fischer Medical Ventures Ltd has announced that its 33rd Annual General Meeting (AGM) will be held on September 29, 2026, at 11:00 AM IST. The meeting will be conducted via Video Conferencing (VC) or Other Audio-Visual Means (OAVM), in compliance with MCA and SEBI circulars. The Annual Report and AGM notice were dispatched to shareholders on September 7, 2026. The cut-off date for determining e-voting rights is September 22, 2026. E-voting will be open from September 26, 2026, 9:00 AM to September 28, 2026, 5:00 PM. The Register of Members and Share Transfer Register will be closed from September 23, 2026, to September 29, 2026.

Fischer Medical Ventures Ltd has announced the record date for determining shareholders eligible for dividend payment and e-voting for the upcoming Annual General Meeting (AGM). The register of members and share transfer books will be closed from September 23, 2026, to September 29, 2026. The record date for dividend and e-voting rights is set for Tuesday, September 22, 2026. Additionally, the cut-off date for receiving the AGM notice is September 4, 2026. The 33rd AGM is scheduled for September 29, 2026.

Fischer Medical Ventures Ltd announced key board decisions following a meeting on September 3, 2026. The company approved the appointment of Mr. David Yeow as an Additional Independent Director for a term of five years, effective September 3, 2026. Following this appointment, the Audit Committee of the Board has been reconstituted. The 33rd Annual General Meeting (AGM) is scheduled for September 29, 2026, to be held via video conferencing. The register of members will be closed from September 23 to September 29, 2026, inclusive, for the AGM.

Fischer Medical Ventures Ltd announced that its wholly owned subsidiary, Time Medical International Ventures (India) Private Ltd. (TMIV Imaging), has launched the CLARION 64/128-Slice AI-Driven CT System in India. The launch took place at the India Health Expo 2026 and was attended by healthcare leaders. The CLARION system integrates advanced engineering, artificial intelligence, and intelligent clinical workflows to enhance diagnostic precision, operational efficiency, and patient care. Key features include an advanced Liquid Metal Bearing X-ray tube, Aegis Detector System for improved image clarity and low-dose imaging, and intelligent workflow capabilities like three-click scanning and AI-assisted patient positioning. The system is available in scalable configurations up to 128 slices and can be adapted for various clinical applications, including interventional and surgical environments.

Fischer Medical Ventures Limited (FMV) announced that its step-down subsidiary, Time Medical Philippines (TM-P), has been awarded a province-wide digital healthcare project in Catanduanes Province, Philippines. The project involves deploying an integrated solution combining Health Kiosks with the PhilHealth-accredited FlynnCare Clinic Management System (CMS). This initiative marks the first province-wide implementation of such an integrated model in the Philippines and is a significant step towards the digitalization of Universal Health Care (UHC) in the country. FMV and TM-P are committed to supporting the Philippine Government's UHC program by enhancing healthcare accessibility and connectivity through digital solutions. The company aims to establish a scalable model for provincial healthcare digitalization, with potential for expansion to other regions.

Fischer Medical Ventures Ltd has announced a disclosure under SEBI's Takeover Regulations regarding an acquisition by FMV Holdings Pte Ltd, along with persons acting in concert (PACs) Mr. Shankar Varadharajan and Mr. Ravindran Govindan. The acquisition, which occurred via Preferential Allotment upon Conversion of warrants, resulted in FMV Holdings Pte Ltd acquiring an additional 4,54,210 equity shares, representing 0.07% of the total diluted share capital. Following this transaction, the combined holding of the acquirer and PACs in Fischer Medical Ventures Ltd stands at 44,07,62,650 shares, constituting 63.08% of the total share capital.

Fischer Medical Ventures Ltd has announced a significant change in its shareholding pattern. Mr. Shankar Varadharajan and Persons Acting in Concert (PACs), including FMV Holdings Pte Ltd and Mr. Ravindran Govindan, have increased their total shareholding to 63.08% of the total diluted share capital. This increase is primarily due to a preferential allotment upon conversion of warrants. The acquisition involved 1,33,35,909 shares, representing 1.91% of the total share capital. Following the acquisition, the total equity shares capital of the company has increased, and the total diluted share capital has also seen an upward revision. The transaction was executed via Preferential Allotment upon Conversion of warrants on August 14, 2026.

Fischer Medical Ventures Ltd has announced a disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, detailing an acquisition by Mr. Shankar Varadharajan and FMV Holdings Pte Ltd, along with Persons Acting in Concert (PAC) Mr. Ravindran Govindan. The acquisition, primarily through a Preferential Allotment upon conversion of warrants, has increased their combined shareholding. Before the acquisition, the acquirer group held approximately 62.66% of the total share capital. After the acquisition, their holding stands at approximately 63.00% of the total share capital and 63.08% of the total diluted share capital. The total equity shares capital of the company has increased post-acquisition.